459 filings
Page 5 of 23
6-K
ujy4k
21 Oct 22
Vesting of awards under the Long Term Incentive Plan
6:09am
6-K
uu5wn1ce4p hec
11 Oct 22
HUTCHMED Initiates a Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China
6:49am
6-K
0vykqgc8j3li m5qpy
30 Sep 22
Current report (foreign)
6:02am
6-K
sdsqj5
14 Sep 22
Grant of Share Options under Share Option Scheme and Awards under
6:17am
6-K
31vesm
8 Sep 22
Current report (foreign)
6:12am
6-K
ad945 y7jnu
23 Aug 22
HUTCHMED Highlights Fruquintinib MRCT FRESCO-2 Data to be Presented at the Upcoming ESMO Congress 2022
6:23am
6-K
rusv qdgv6kd0
9 Aug 22
Inmagene and HUTCHMED Announce First Participant in Global Phase I Trial of IMG-004
6:21am
6-K
mwxdk1xcv2
8 Aug 22
HUTCHMED Announces that Fruquintinib Global Phase III FRESCO-2 Study Has Met Its Primary Endpoint in Metastatic Colorectal Cancer
6:24am
6-K
j8ba1 wn5
1 Aug 22
HUTCHMED Reports 2022 Interim Results and Provides Business Updates
7:33am
6-K
p5mqk08cgpout7ngoib
1 Aug 22
Current report (foreign)
6:53am
UPLOAD
mqe3edv88uv8 ajeih
28 Jul 22
Letter from SEC
12:00am
CORRESP
74k3v0cgw7 2o
25 Jul 22
Correspondence with SEC
12:00am
UPLOAD
ofaets xo6ylykm3
21 Jul 22
Letter from SEC
12:00am
6-K
xcjq9
15 Jul 22
Current report (foreign)
6:26am
6-K
r5bkqy
13 Jul 22
HUTCHMED Highlights First Presentation of Results of the SAVANNAH Global Phase II Trial of Savolitinib plus TAGRISSO® at the 2022 WCLC Annual Meeting
7:19am
6-K
m8m6rqds ik16ypmu
6 Jul 22
Inmagene and HUTCHMED Announce First Participants in Global Phase I Trial of IMG-007
6:15am
6-K
c1yqi cy7
30 Jun 22
Current report (foreign)
6:08am
6-K
09sxbuit
29 Jun 22
Current report (foreign)
6:27am
6-K
plbzn 5bx7
27 Jun 22
HUTCHMED to Announce 2022 Half-Year Financial Results
6:20am
CORRESP
x5rdr erl8m
8 Jun 22
Correspondence with SEC
12:00am